U.S. Metals and Mining Stock News

Wondering if BeOne Medicines at around US$296.97 is offering fair value or a mispriced opportunity? This breakdown is designed to help you think clearly about what the market is paying for today. The stock has moved 7.7% over the last 7 days, while the 30 day return stands at a 6.3% decline and the year to date return is a 4.5% decline, with a 9.6% return over the past year and 38.1% over 3 years, set against a 9.8% decline over 5 years. Recent coverage around BeOne Medicines has focused on...

For readers considering whether Deckers Outdoor is attractively priced or whether the market has already moved ahead of itself, this breakdown is intended to help you weigh what the current share price reflects. The stock recently closed at US$100.09, with returns of a 1.3% decline over 7 days, a 14.6% decline over 30 days, a 6.3% decline year to date and an 11.7% decline over 1 year, set against longer term returns of 31.9% over 3 years and 77.2% over 5 years. Recent share price moves have...

Wondering if Benchmark Electronics at US$53.53 is priced fairly for what you are getting, or if the market is missing something. The stock has pulled back 6.2% over the last week and 7.4% over the last month, even though the year to date return is 21.9% and the 1 year return is 43.0%. Over a longer stretch, the stock has recorded a 139.0% return across 3 years and 85.2% over 5 years. The recent weakness therefore sits against a much stronger multi year record, and that mix of shorter term...

Adaptive Biotechnologies (NasdaqGS:ADPT) President and COO Julie Rubinstein recently sold shares under a pre-arranged trading plan. The transaction reduced her direct holdings and was executed as a scheduled, non-discretionary insider sale. The sale comes as the company reports clonoSEQ revenue performance and points to a path toward profitability. Adaptive Biotechnologies focuses on immune-driven diagnostics and uses its immune medicine platform to support blood cancer monitoring through...

Intellicheck, Inc. has already reported its full-year 2025 results, with sales rising to US$22.67 million from US$20.00 million and net income improving to US$1.27 million from a US$0.92 million loss a year earlier. The shift from loss to profit, alongside positive basic and diluted earnings per share from continuing operations, underscores a clear improvement in Intellicheck’s operating performance and cost discipline. With Intellicheck’s move to full-year profitability now confirmed, we’ll...

Earlier today, UBS reiterated its Buy rating on Performance Food Group, citing the distributor’s exposure to independent restaurants as a key strength within the evolving foodservice landscape. UBS’s commentary, framed against Sysco’s Restaurant Depot acquisition, highlights how cash-and-carry and independent restaurant trends are reshaping competitive positioning in food distribution. We’ll now examine how this renewed focus on independent restaurants potentially influences Performance Food...

DorianG (LPG) has drawn attention after recent share price swings, with a one-month return of about a 10% decline and a past three months gain of roughly 38%, prompting investors to reassess its valuation. See our latest analysis for DorianG. Zooming out from the recent pullback, DorianG’s share price has a 30 day return of about a 10% decline, but a year to date gain of 34.1%. The 1 year total shareholder return of 62.2% and 5 year total shareholder return of about 4.7x point to stronger...

TriCo Bancshares (TCBK) has filed a shelf registration for up to 1,200,000 shares of common stock, totaling about $56.892 million, linked to an employee stock ownership plan that could influence future capital planning. See our latest analysis for TriCo Bancshares. At a share price of $47.09, TriCo Bancshares has seen modest short term share price softness. Its 1 year total shareholder return of 21.54% suggests longer term momentum has been stronger, with the ESOP related shelf registration...

Wondering if JBS at around US$17.34 actually offers value or if the easy gains are gone? This breakdown will help you weigh what the current price might really reflect. The stock has delivered a 15.1% return over the last 7 days, 2.7% over the past 30 days, and 22.3% year to date, which has likely sharpened attention on both its potential and its risks. Recent coverage has focused on JBS as a major player in the global food and meat supply chain, with attention on topics such as industry...

Rayonier (NYSE:RYN) has appointed KPMG as its independent auditor for the 2026 fiscal year audit. The company will transition from its current auditor, Ernst & Young, as part of this change. Rayonier reported that the switch did not arise from disagreements on accounting practices or adverse audit opinions. For investors watching Rayonier at a share price of $20.6, the auditor change follows a challenging stretch for the stock. NYSE:RYN has seen a 17.8% decline over the past year and a...

If you are wondering whether SkyWater Technology's recent run still offers value, or if you might be late to the story, this article will walk through what the current price could be implying. The stock trades at US$26.18 after a 10.5% pullback over the last week and 11.1% over the last month, yet it still sits on a 16.7% year-to-date return and a 269.3% return over the past year. These moves come as SkyWater continues to attract attention as a specialized semiconductor foundry, with...

Wondering if Old National Bancorp at around US$21.48 is offering fair value or a potential mispricing opportunity? This article breaks down what the current share price might really be telling you. The stock has seen a 0.3% decline over the past week and a 7.0% decline over the past month, while still sitting on a 4.0% return over the last year and a 65.0% return over three years. This can signal changing views on both growth potential and risk. Recent coverage has focused on Old National...

Plains GP Holdings filed a new shelf registration for its Class A common shares. The filing gives the company flexibility to issue new equity securities in the future. The move is a material corporate action that can affect funding plans and existing shareholders. Plains GP Holdings (NasdaqGS:PAGP) last closed at $24.42, with the shares showing returns of 2.8% over the past week and 8.3% over the past month. Over longer periods, the stock has returns of 25.8% year to date and 24.1% over the...

The United States market has experienced a 3.5% decline over the past week, yet it remains up by 14% over the last year with anticipated earnings growth of 15% annually in the coming years. In this fluctuating environment, identifying stocks that may be trading below their estimated worth can provide opportunities for investors seeking value amidst broader market trends.

Over the last 7 days, the United States market has experienced a 3.5% decline, yet it remains up by 14% over the past year with earnings forecasted to grow by 15% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often align management interests with shareholders and may offer resilience amid market fluctuations.

Progressive (NYSE:PGR) has completed two major fixed income offerings totaling more than $1.4b in senior unsecured notes. The new notes mature in 2031 and 2036, adding longer dated debt to the company’s capital structure. AM Best assigned an 'a' (Excellent) credit rating and a stable outlook to these new unsecured notes. Progressive, trading at $201.39, comes into this debt issuance with a mixed share price record, including a 24.2% decline over the past year and gains of 51.9% over three...

Over the last 7 days, the United States market has dropped 3.5%, but it has seen a rise of 14% over the past year, with earnings projected to grow by 15% annually in coming years. In light of these conditions, identifying stocks with strong financial health and growth potential is crucial for investors seeking opportunities beyond mainstream options. Penny stocks, though an outdated term, still represent a niche investment area that can offer surprising value and potential returns when backed...

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 14% over the past year, with earnings anticipated to grow by 15% annually in the coming years. In this dynamic environment, identifying stocks that are not only resilient but also poised for growth can be a rewarding strategy for investors seeking potential opportunities.

Over the last 7 days, the United States market has experienced a 3.5% drop, although it has shown resilience with a 14% rise over the past year and an earnings growth forecast of 15% annually. In this context, dividend stocks that offer consistent payouts and potential for long-term appreciation can be attractive options for investors seeking stability amidst fluctuating market conditions.

Steel Dynamics (NasdaqGS:STLD) announced that long serving directors Richard P. Teets, Jr. and Gabriel L. Shaheen plan to retire from its board at the upcoming annual meeting. The changes will reduce long term board presence and open seats for new directors once shareholders vote at the meeting. Both directors have served during key phases of the company’s development in the steel and metals recycling sector. For you as an investor, this matters because board composition shapes how Steel...

New independent cost impact model evaluates Indivior's extended-release buprenorphine (SUBLOCADE) in U.S. correctional facilities. The model suggests SUBLOCADE, a monthly injectable for opioid use disorder, may meaningfully cut staff time and related costs versus other treatments. Findings, published in a peer reviewed journal, highlight potential operational benefits and treatment access gains for jails and prisons. For investors watching Indivior Pharmaceuticals (NasdaqGS:INDV), this...

Wondering whether CubeSmart's current share price still offers value, or if most of the opportunity has already been priced in? This article breaks down what the numbers actually say about the stock. CUBE has had a mixed run recently, with a 3.4% decline over 7 days, a 12.7% decline over 30 days, a 1.4% gain year to date, and an 11.4% decline over the last year, which can change how the market views its risk and return profile. Recent coverage has focused on CubeSmart's share price moves and...

Wondering if DRDGOLD at around US$27.65 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price might imply. The stock has returned 1.7% over the last 7 days, while the 30 day return sits at a 28.9% decline, against an 8.8% decline year to date and an 81.5% return over the past year, with a very large 3 year and 226.1% 5 year return. Recent coverage has focused on DRDGOLD as part of broader gold and precious metals...

Recently, BioMarin Pharmaceutical discontinued three Phase 2 Voxzogo studies following safety concerns, while simultaneously reporting encouraging clinical and real-world outcomes for the drug in other settings. The company and analysts now suggest that Voxzogo’s safety issues may be limited to specific uses, with BioMarin’s broader outlook increasingly supported by its wider rare-disease portfolio. Now we’ll explore how the Voxzogo safety-driven trial discontinuations, alongside positive...